[{"data":1,"prerenderedAt":168},["ShallowReactive",2],{"drug-terlipressin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":36,"contraindications":64,"warnings":74,"renal":89,"monitoring":90,"interactions":91,"review":92,"examples":95,"atc":101,"iran":103,"links":110,"populations":128,"usApproval":163},"terlipressin",1,{"fa":7,"en":8},"ترلیپرسین","Terlipressin","systemic-hormones",{"fa":11,"en":12},"آنالوگ وازوپرسین","Vasopressin analogue",[14],{"name":15,"market":16},"Terlivaz","US",[18,19,20,7],"terlivaz","glypressin","گلیپرسین",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"vial-0-85","powder-for-injection","iv","0.85 mg vial",{"amount":28,"unit":29,"perUnit":30},0.85,"mg","vial",[16],[33],{"source":34,"section":35},"fda-terlivaz","3",[37],{"id":38,"disease":39,"label":40,"population":43,"type":47,"unit":29,"dose":48,"refs":50,"notes":53},"hrs","hepatorenal-syndrome",{"fa":41,"en":42},"سندرم هپاتورنال با کاهش سریع عملکرد کلیه — ۰٫۸۵ mg بولوس وریدی آهسته (۲ دقیقه) هر ۶ ساعت، روز ۱ تا ۳","Hepatorenal syndrome with rapid reduction in kidney function — 0.85 mg slow IV bolus (2 min) every 6 h, days 1–3",{"minAge":44},{"value":45,"unit":46},18,"year","fixed",{"perDose":28,"dosesPerDay":49},4,[51],{"source":34,"section":52},"2.2",[54],{"text":55,"refs":58},{"fa":56,"en":57},"روز ۴: اگر کراتینین ۳۰٪ یا بیشتر کاهش یافته ادامه؛ کمتر: طبق نمودار برچسب افزایش تا ۱٫۷ mg. پیش از شروع SpO2 و درجه ACLF؛ پالس‌اکسی‌متری مداوم.","Day 4: continue if creatinine fell ≥30%; less: may increase per label chart (to 1.7 mg). Check SpO2 and ACLF grade first; continuous pulse oximetry.",[59,60,62],{"source":34,"section":52},{"source":34,"section":61},"2.1",{"source":34,"section":63},"2",[65],{"id":66,"severity":67,"text":68,"refs":71},"ci","block",{"fa":69,"en":70},"هیپوکسی یا بدتر شدن علائم تنفسی؛ ایسکمی کرونر، محیطی یا مزانتریک فعال.","Hypoxia or worsening respiratory symptoms; ongoing coronary, peripheral or mesenteric ischaemia.",[72],{"source":34,"section":73},"4",[75,82],{"text":76,"refs":79},{"fa":77,"en":78},"هشدار جعبه‌ای: نارسایی تنفسی جدی یا کشنده (بیشتر با حجم اضافه یا ACLF درجه ۳) — SpO2 زیر ۹۰٪ شروع نشود یا قطع شود.","Boxed warning: serious or fatal respiratory failure (higher with volume overload or ACLF grade 3) — do not start or stop if SpO2 \u003C90%.",[80],{"source":34,"section":81},"Boxed Warning",{"text":83,"refs":86},{"fa":84,"en":85},"ایسکمی؛ عدم واجد شرایط شدن برای پیوند کبد؛ سمیت جنینی.","Ischaemic events; ineligibility for liver transplant; embryo-fetal toxicity.",[87],{"source":34,"section":88},"5",[],[],[],{"status":93,"reviewer":94,"date":94},"unverified",null,[96],{"regimen":38,"formulation":23,"input":97,"expect":100},{"ageYears":98,"weightKg":99},55,75,{"perDose":28,"dosesPerDay":49},[102],"H01BA04",{"status":104,"refs":105},"not-found",[106],{"source":107,"section":108,"url":109},"darooyab-generic","G-2721\u002FTerlipressin","https:\u002F\u002Fwww.darooyab.ir\u002FG-2721\u002FTerlipressin",[111,115,119,123,126],{"kind":112,"url":113,"label":114},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022231","NDA022231",{"kind":116,"url":117,"label":118},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=3a35b86c-f451-4fac-8499-43019e4da354","FDA Terlivaz",{"kind":120,"url":121,"label":122},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa625010.html","Terlipressin Injection",{"kind":124,"url":125,"label":102},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=H01BA04",{"kind":127,"url":109,"label":8},"darooyab",{"pregnancy":129,"lactation":138,"pediatric":147,"geriatric":155},{"level":130,"text":131,"quote":134,"refs":135},"avoid",{"fa":132,"en":133},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Based on findings from the published literature and on its mechanism of action, TERLIVAZ may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] .",[136],{"source":34,"section":137},"8.1",{"level":139,"text":140,"quote":143,"refs":144},"caution",{"fa":141,"en":142},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of terlipressin in human or animal milk, the effects on the breastfed infant, or the effect on milk production.",[145],{"source":34,"section":146},"8.2",{"level":139,"text":148,"quote":151,"refs":152},{"fa":149,"en":150},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of TERLIVAZ have not been established in pediatric patients.",[153],{"source":34,"section":154},"8.4",{"level":139,"text":156,"quote":159,"refs":160},{"fa":157,"en":158},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total number of patients in clinical studies treated with TERLIVAZ, 55 (16%) were ≥65 years of age.",[161],{"source":34,"section":162},"8.5",{"kind":164,"refs":165,"id":114},"NDA",[166],{"source":34,"section":167},"SPL approval \u002F marketing category",1792444425582]